CTWG Steering Committee System
The Steering Committees strive to enhance the National Cancer Clinical Trials Enterprise through the implementation of Prioritization/Scientific Quality Initiatives 1, 2, and 3 of the CTWG Report (PDF - 366KB).
Goals of the Committees
Scientific Steering Committees (SSCs) are composed of leading cancer experts and advocates from outside the Institute as well as NCI senior investigators who meet regularly to:
- increase the transparency and openness of the trial design and prioritization process;
- enhance patient advocate and community oncologist involvement in clinical trial design and prioritization;
- convene Clinical Trial Planning Meetings to identify critical questions, unmet needs, and prioritize key strategies.
SSCs may establish one or more Task Forces and/or Working Groups that focus on specific diseases or scientific areas of interest.
Disease-Specific Steering Committees (DSSC):
Brain Malignancies Steering Committee
Breast Cancer Steering Committee
Gastrointestinal Steering Committee
Genitourinary Steering Committee
Gynecologic Steering Committee
Head and Neck Steering Committee
Leukemia Steering Committee
Lymphoma Steering Committee
Myeloma Steering Committee
Pediatric and Adolescent Solid Tumor Steering Committee
Pediatric Leukemia and Lymphoma Steering Committee
Thoracic Malignancy Steering Committee
Roles of the Committees are to:
Leverage current Intergroup, Cooperative Group, SPORE, and Cancer Center structures by:
- increasing information exchange at an early stage of trial development;
- increasing the efficiency of clinical trial collaboration;
- reducing trial redundancy (phase II and phase III);
- developing, evaluating, and prioritizing concepts for phase III and large phase II clinical trials.
Role of the Committee is to:
- achieve optimal phase I and phase II trial designs for the most promising agents;
- increase the predictive value of early phase trials, in order to design more successful phase III trials.
Role of the Committee is to:
- review and prioritize symptom management intervention clinical trial concepts to be conducted through the CCOP mechanism;
- provide input to studies with secondary quality-of-life (QOL) endpoints in cooperative group treatment studies;
- develop prioritization criteria for QOL studies that are eligible for proposed correlative science/QOL set aside funds.
Role of the Committee is to:
- develop and share best practices for patient advocates in Scientific Steering Committees;
- identify common concerns and needs and propose potential solutions to address theses concerns;
- disseminate Scientific Steering Committee information to the appropriate communities;
- ensure that the concept evaluations consider the patient community at large, with a special focus on minority and underserved populations.
Role of the Committee is to:
- identify and promote the "Best Science" by addressing the design and prioritization of phase III and large phase II trials focused primarily on cancer imaging;
- serve as a forum for the extramural imaging and oncology communities to provide strategic input to NCI regarding its significant investment in imaging activities in clinical trials;
- provide valuable imaging expertise for other steering committees' evaluations of therapeutic concepts and discussions that include an imaging component.
Clinical Trials Planning Meetings (CTPMs)
The goal of CTPMs is to:
-
identify strategic directions for clinical trials in a specific field
- reach consensus on the most important clinical trials to conduct;
- identify portfolio gaps and emerging scientific opportunities;
- identify innovative trial design opportunities;
- facilitate innovation and collaboration among the broad oncology community active in the specific cancer under study
CTPM Executive Summaries:
- BCSC-BCSC ER+ CTPM - Executive Summary (May 14-15, 2012)
- PASTSC-Neuroblastoma CTPM - Executive Summary (April 12-13, 2012)
- TMSC-TMSC CTPM - Executive Summary (February 2-3, 2012)
- GCSC-Ovarian CTPM - Executive Summary (October 28-29, 2011)
- SxQOL SC-SxQOL PRO CTPM Executive Summary (September 22-23, 2011)
- BCSC-BCSC HER2 CTPM - Executive Summary (May 16-17, 2011)
- MYSC-Multiple Myeloma Meeting, Conclusions and Recommendations (Mar 2, 2011)
- GISC-Colon and Rectal Cancers CTPM - Executive Summary (Jan 7-8, 2011)
- LKSC-CLL Working Group Meeting - Executive Summary (Nov 17, 2010)
- LKSC-AML Working Group Meeting - Executive Summary (Oct 4, 2010)
- LYSC-DLBCL Working Group Meeting - Executive Summary (Oct 31, 2010)
- SxQOL-Cancer-Related Fatique, Executive Summary (April 13-14, 2010)
- GISC-Neuroendocrine Tumors CTPM - Executive Summary (Nov 20-21, 2009)
- GISC-Gastrointestinal Stromal Tumors CTPM - Executive Summary (April 16, 2009)
- SxQOL-Chemotherapy-induced Peripheral Neuropathy CTPM - Executive Summary (March 23, 2009)
- GISC-Hepatocellular Carcinoma (HCC) CTPM - Executive Summary (Dec 12-13, 2008)
- HNSC- Squamous Cell Cancer and the Human Papillomavirus - Executive Summary (Nov. 9-10, 2008)
- GCSC-Cervical Cancer State of the Science Meeting (Sept. 27-28, 2007)
- GCSC-Endometrial Cancer State of the Science Meeting, Executive Summary (Nov. 28-29, 2006)
CTPM Publications: